Posts Tagged: "methicillin resistant staphylococcus aureus"

FDA approval of Teflaro puts Allergan’s portfolio of anti-infectives into focus

Treatments for infectious diseases is one area where Allergan is looking to buoy its fortunes in the coming years. The first quarter of 2016 was a strong one for Allergan, which saw its overall revenues increase by 48 percent when compared to 2015’s first quarter; revenue for Allergan’s branded pharmaceutical divisions grew by 71 percent year-over-year. The company’s infectious disease division was not its most profitable and yet it saw the greatest amount of growth compared to the previous year. Teflaro entered the Allergan portfolio thanks to a series of acquisitions in the biopharma realm over the past few years. The pediatric anti-infective was first developed by Forest Laboratories, formerly of New York City, which was acquired by Actavis in February 2014 for a combination of cash and equity which reached a reported $25 billion.

Sherwin-Williams Paint Shield offers antibacterial protection against MRSA

MRSA, or methicillin-resistant Staphylococcus aureus, is a bacteria highly resistant to antibiotics and causes tens of thousands of invasive infections every year in Americans, often in hospital or nursing home settings. Patients who may be susceptible to any bacterial infections of this type will be able to breathe a great sigh of relief thanks to a new paint formula developed by Sherwin-Williams Co. (NYSE:SHW) of Cleveland, OH. The buildings material developer, known primarily for its paint products, announced at the end of October a new antimicrobial paint formulation known as Paint Shield which will begin selling in the first quarter of 2016. A Sherwin-Williams press release states that this is the first U.S. Environmental Protection Agency-registered paint capable of killing up to 99.99 percent of staph, MRSA, E. coli and other infection-causing bacteria within two hours of the bacteria’s exposure to the paint.